Jonathan Gillis, Chief Accounting Officer and Interim Chief Financial Officer, on July 15, 2026, sold 36,979 shares in Maplight Therapeutics (MPLT) for $1,372,668. Following the Form 4 filing with the SEC, Gillis has control over a total of 144,240 voting common shares of the company, with 144,240 shares held directly.
SEC Filing: